Showing results (301-310 of 501) with videos related to

Sort By:
Pageof 51
Nature Biotechnology|October 21, 2025
Integrated epigenetic and genetic programming of primary human T cellsLaine Goudy, Alvin Ha, Ashir A Borah, et al.
Prostate Cancer and Prostatic Diseases|July 21, 2021
Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborativeRandy A Vince, Ralph Jiang, Ji Qi, et al.
British Journal of Cancer|November 19, 2023
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)Jimmy L Zhao, Emmanuel S Antonarakis, Heather H Cheng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 3, 2024
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926Douglas M Dahl, Joseph P Rodgers, William U Shipley, et al.
Asian Journal of Urology|December 22, 2017
Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy seriesZachary B Koloff, Daniel A Hamstra, John T Wei, et al.
Urologic Oncology|May 24, 2017
Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomyDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2020
Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate CancerYingming Li, Rendong Yang, Christine M Henzler, et al.
Cell|April 10, 2021
Genome-wide programmable transcriptional memory by CRISPR-based epigenome editingJames K Nuñez, Jin Chen, Greg C Pommier, et al.
European Urology|February 27, 2018
Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate CancerBrandon A Mahal, David D Yang, Natalie Q Wang, et al.
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Pageof 51